GD2-CAR-Engineered Microglia Exhibit Antitumor Effects in Organoids and Animal Models of Retinoblastoma. [PDF]
Xu J +6 more
europepmc +1 more source
Target antigen-displaying extracellular vesicles boost CAR T cell efficacy in cell and mouse models of neuroblastoma. [PDF]
Giudice AM +20 more
europepmc +1 more source
Targeting Sphingolipids in Breast Cancer: From Tumor Biology to Therapeutic Strategies. [PDF]
Kim MH, Huh B, Park JW, Park WJ.
europepmc +1 more source
X-optogenetic inhibition of VTA GABA neurons for wireless deep-brain stimulation and suppression of scratching behavior in freely moving mice. [PDF]
Lan B +9 more
europepmc +1 more source
Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases. [PDF]
Aries C +7 more
europepmc +1 more source
Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities. [PDF]
Choo HS, Yu T, Pham T, Singh N, Joshi S.
europepmc +1 more source
BACH2 dosage establishes the hierarchy of stemness and fine-tunes antitumor immunity in CAR T cells. [PDF]
Hu T +8 more
europepmc +1 more source
Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a chimeric monoclonal antibody ch14.18.
Tatjana, Terzic +8 more
openaire +3 more sources
Related searches:
Disialoganglioside GD2 as a therapeutic target for human diseases
Expert Opinion on Therapeutic Targets, 2015Ganglioside GD2 is found in vertebrates and invertebrates, overexpressed among pediatric and adult solid tumors, including neuroblastoma, glioma, retinoblastoma, Ewing's family of tumors, rhabdomyosarcoma, osteosarcoma, leiomyosarcoma, liposarcoma, fibrosarcoma, small cell lung cancer and melanoma.
Maya Suzuki
exaly +3 more sources

